U.S. Markets closed

Allergan Slides Following Rejection of Valeant Takeover Bid

Shares of Allergan lost one percent on Monday, making it TheStreet's move of the day. The drugmaker rejected Valeant Pharmaceuticals International's $47 billion takeover bid, calling its rival's business model unsustainable and saying that too much uncertainty remains about Valeant's long-term outlook. Allergan said in a letter to Valeant CEO Michael Peterson on Monday, "[Your] Proposal includes a large stock component, which we believe is a risk for Allergan stockholders due to the uncertainty surrounding Valeant's long term growth prospects and business model." TheStreet's Joe Deaux breaks down the move from New York.